[
  {
    "ts": "2025-11-17T11:50:00+00:00",
    "headline": "BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification",
    "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries.",
    "url": "https://finance.yahoo.com/news/bd-onclarity-hpv-assay-bd-115000067.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b549b92d-a8c9-35a3-b87d-810808879b3d",
      "content": {
        "id": "b549b92d-a8c9-35a3-b87d-810808879b3d",
        "contentType": "STORY",
        "title": "BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification",
        "description": "",
        "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries.",
        "pubDate": "2025-11-17T11:50:00Z",
        "displayTime": "2025-11-17T11:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/fadb53c4f3bb1c505c358087f2fe898e",
          "originalWidth": 400,
          "originalHeight": 224,
          "caption": "BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ji3BSwpcg1u6f7fhXtOcCg--~B/aD0yMjQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fadb53c4f3bb1c505c358087f2fe898e.cf.webp",
              "width": 400,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KYHbloMwxIEWTsyi4QgM7w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fadb53c4f3bb1c505c358087f2fe898e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bd-onclarity-hpv-assay-bd-115000067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bd-onclarity-hpv-assay-bd-115000067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BDX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]